Non-Insulin Therapies For Diabetes Global Market Report 2025
상품코드:1825837
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
당뇨병 비인슐린 요법 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 연평균 성장률(CAGR) 6.2%로 269억 8,000만 달러로 성장할 것입니다. 예측 기간의 성장은 당뇨병 유병률 증가, 당뇨병 관리에 대한 인식 증가, 병용요법 채택 확대, 고령 인구 증가, 의료비 지출 증가, 원격의료 확대, 경구용 약물 선호도 증가 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 경구약과 주사제의 발전, 약물전달 시스템의 발전, 경구 펩타이드 전달의 발전, 원격의료 및 디지털 헬스 솔루션의 채택, 병용요법의 발전 등을 들 수 있습니다.
향후 5년간 6.2%의 성장률 전망은 지난번 예측보다 0.6% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 덴마크와 인도에서 조달하는 글루카곤 유사 펩타이드-1 수용체 작용제 GLP-1 수용체 작용제 및 나트륨-포도당 공수송체 2 억제제 SGLT2 억제제 비용을 상승시키고, 당뇨병 관리 옵션을 좁히고, 내분비학 지출을 증가시킴으로써 미국을 저해할 것으로 예상됩니다. 억제할 것으로 예상됩니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
당뇨병 유병률의 증가는 향후 당뇨병 비인슐린 요법 시장의 성장을 견인할 것으로 예상됩니다. 당뇨병은 혈당 상승을 특징으로 하는 만성질환으로 체내에서 인슐린이 충분히 분비되지 않거나 분비된 인슐린을 적절히 이용하지 못할 때 발생합니다. 당뇨병 환자의 증가는 좌식 생활습관, 건강에 해로운 식습관, 유전적 소인, 고령화, 비만, 민족성, 인식 부족, 의료 서비스 접근성 제한, 환경적 요인과 관련이 있습니다. 당뇨병의 비인슐린 요법은 인슐린 감수성을 높이고, 간에서 포도당 생성을 감소시키고, 근육 세포의 포도당 흡수를 촉진하고, 전반적인 혈당 조절을 개선하여 병을 관리하는 데 도움이 될 수 있습니다. 예를 들어, 2023년 4월 영국의 당뇨병 자선단체인 영국 당뇨병 협회의 보고에 따르면, 영국에서 430만 명이 당뇨병 진단을 받았습니다. 2021-22년 등록 데이터에 따르면, 2020-21년 대비 14만 8,951건이 증가했으며, 240만 명 이상이 제2형 당뇨병 발병 위험이 높은 것으로 나타났습니다. 그 결과, 당뇨병 유병률의 증가가 당뇨병 비인슐린 요법 시장의 확대를 주도하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 당뇨병 비인슐린 요법 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 당뇨병 비인슐린 요법 시장 : 성장률 분석
세계의 당뇨병 비인슐린 요법 시장 실적 : 규모와 성장, 2019-2024
세계의 당뇨병 비인슐린 요법 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 당뇨병 비인슐린 요법 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 당뇨병 비인슐린 요법 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
비구아나이드
설포닐우레아
치아졸리딘디온
알파 글루코시다아제 억제제
디펩티딜 펩티다아제-4(DPP-4) 억제제
글루카곤 유사 펩타이드-1(GLP-1) 유사체
나트륨-글루코스 공수송체-2(SGLT2) 억제제
세계의 당뇨병 비인슐린 요법 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
근육내
세계의 당뇨병 비인슐린 요법 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
소매 약국
병원 약국
온라인 약국
세계의 당뇨병 비인슐린 요법 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
모니터링
진단
치료
기타 용도
세계의 당뇨병 비인슐린 요법 시장 : 하위 세분화 비구아나이드 약(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
메트포르민
메트포르민과 기타 약제 병용
세계의 당뇨병 비인슐린 요법 시장 : 하위 세분화 설포닐우레아 약(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
글리메피리드
글리피지드
글리부라이드
세계의 당뇨병 비인슐린 요법 시장 : 하위 세분화 치아졸리딘디온(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
피오글리타존
로시글리타존
세계의 당뇨병 비인슐린 요법 시장 : 하위 세분화 α-글루코시다아제 억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
아카보스
미글리톨
세계의 당뇨병 비인슐린 요법 시장 : 하위 세분화 디펩티딜 펩티다아제-4(DPP-4) 억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
시타글립틴
삭사글립틴
리나글립틴
알로글립틴
세계의 당뇨병 비인슐린 요법 시장 : 하위 세분화 글루카곤 유사 펩타이드-1(GLP-1) 유사체(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
엑세나타이드
리라글루타이드
둘라글루타이드
세마글루타이드
세계의 당뇨병 비인슐린 요법 시장 : 하위 세분화 나트륨-글루코스 공수송체-2(SGLT2) 억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
카나글리플로진
다파글리플로진
엠파글리플로진
제7장 지역별·국가별 분석
세계의 당뇨병 비인슐린 요법 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 당뇨병 비인슐린 요법 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
당뇨병 비인슐린 요법 시장 : 경쟁 구도
당뇨병 비인슐린 요법 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi Overview, Products and Services, Strategy and Financial Analysis
The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
AstraZeneca plc
Novartis AG
GSK plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Novo Nordisk A/S
Boehringer Ingelheim International GmbH
Les Servier Laboratories
Sumitomo Dainippon Pharma Co. Ltd.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
Uni-Bio Science Group Ltd.
Intarcia Therapeutics
Janssen Pharmaceuticals
Boan Biotech
SatRx LLC
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
당뇨병 비인슐린 요법 시장 2029 : 새로운 기회를 제공하는 국가
당뇨병 비인슐린 요법 시장 2029 : 새로운 기회를 제공하는 부문
당뇨병 비인슐린 요법 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Non-insulin therapies for diabetes are treatments and medications designed to manage blood sugar levels in diabetic patients without the need for insulin injections. These therapies play a crucial role in regulating blood glucose levels for patients who either do not require insulin or prefer alternative methods of treatment.
The primary classes of drugs in the non-insulin therapies for diabetes market include biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Biguanides, for instance, are oral hypoglycemic agents that target type 2 diabetes by reducing liver glucose production and improving insulin sensitivity. These medications can be administered orally or intramuscularly and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies. They are utilized for purposes such as monitoring, diagnosis, treatment, and more.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The non-insulin therapies for diabetes market research report is one of a series of new reports from The Business Research Company that provides non-insulin therapies for diabetes market statistics, including the non-insulin therapies for diabetes industry global market size, regional shares, competitors with non-insulin therapies for diabetes market share, detailed non-insulin therapies for diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the non-insulin therapies for diabetes industry. These non-insulin therapies for diabetes market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $19.98 billion in 2024 to $21.21 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increasing diabetes prevalence, increasing awareness of diabetes management, rise in healthcare expenditure, shift in lifestyle changes leading to higher incidence rates, surge in diagnosis, increasing government initiatives for diabetes care, and increasing investment in pharmaceutical R&D.
The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $26.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing awareness of diabetes management, growing adoption of combination therapies, expanding geriatric population, increasing healthcare expenditure, expansion of telemedicine, and growing preference for oral medications. Major trends in the forecast period include advancements in oral and injectable medications, advancements in drug delivery systems, advancements in oral peptide delivery, adoption of telemedicine and digital health solutions, and advancements in combination therapies.
The forecast of 6.2% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of Glucagon-Like Peptide-1 receptor agonists GLP-1 receptor agonists and Sodium-Glucose cotransporter 2 inhibitors SGLT2 inhibitors sourced from Denmark and India, thereby limiting diabetes management options and elevating endocrinology expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of diabetes is anticipated to drive the growth of the non-insulin therapies market for diabetes in the future. Diabetes is a chronic condition marked by elevated blood glucose (sugar) levels, occurring when the body cannot produce adequate insulin or properly utilize the insulin it produces. The increase in diabetes cases is linked to sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited healthcare access, and environmental factors. Non-insulin therapies for diabetes aid in managing the condition by enhancing insulin sensitivity, lowering glucose production in the liver, boosting glucose uptake in muscle cells, and improving overall glycemic control. For example, in April 2023, a report from The British Diabetic Association, a UK-based diabetes charity, indicated that 4.3 million people in the UK had been diagnosed with diabetes. Registration data for 2021-22 reflected a rise of 148,951 cases compared to 2020-21, with over 2.4 million individuals at high risk of developing type 2 diabetes. Consequently, the growing prevalence of diabetes is driving the expansion of the non-insulin therapies market for diabetes.
Leading companies in the non-insulin therapies market are focusing on personalized diabetes management systems to improve patient outcomes through real-time monitoring, data analysis, and customized treatment plans. Personalized systems adapt treatment strategies and monitoring based on individual patient needs, leveraging real-time data and analytics to optimize care. For instance, Eli Lilly and Company introduced the Tempo personalized diabetes management platform in November 2022. This platform integrates the Tempo Smart Button, TempoSmart app, and prefilled insulin pen (Tempo Pen) to deliver tailored guidance for adults with diabetes. The technology assists both type 1 and type 2 diabetes patients and their healthcare providers in making informed, data-driven treatment decisions using Lilly insulins.
In August 2023, Eli Lilly and Company acquired Sigilon Therapeutics Inc. for $309.6 million, enhancing its research and development efforts in encapsulated cell therapies such as SIG-002 for type 1 diabetes treatment. This acquisition reflects Lilly's commitment to advancing solutions that alleviate the continuous disease management burden for individuals with type 1 diabetes. Sigilon Therapeutics Inc. is a biopharmaceutical company specializing in encapsulated cell therapies for type 1 diabetes treatment.
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the non-insulin therapies for diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-Insulin Therapies For Diabetes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on non-insulin therapies for diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non-insulin therapies for diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-insulin therapies for diabetes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Non-Insulin Therapies For Diabetes Market Characteristics
3. Non-Insulin Therapies For Diabetes Market Trends And Strategies
4. Non-Insulin Therapies For Diabetes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Non-Insulin Therapies For Diabetes Growth Analysis And Strategic Analysis Framework
5.1. Global Non-Insulin Therapies For Diabetes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Insulin Therapies For Diabetes Market Growth Rate Analysis
5.4. Global Non-Insulin Therapies For Diabetes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Insulin Therapies For Diabetes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Insulin Therapies For Diabetes Total Addressable Market (TAM)
6. Non-Insulin Therapies For Diabetes Market Segmentation
6.1. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.2. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intramuscular
6.3. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
6.4. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monitoring
Diagnosis
Treatment
Other Applications
6.5. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metformin
Combination Of Metformin With Other Drugs
6.6. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Glimepiride
Glipizide
Glyburide
6.7. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pioglitazone
Rosiglitazone
6.8. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acarbose
Miglitol
6.9. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
6.10. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Glucagon-Like Peptide-1 (GLP-1) Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Exenatide
Liraglutide
Dulaglutide
Semaglutide
6.11. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Canagliflozin
Dapagliflozin
Empagliflozin
7. Non-Insulin Therapies For Diabetes Market Regional And Country Analysis
7.1. Global Non-Insulin Therapies For Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Insulin Therapies For Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Non-Insulin Therapies For Diabetes Market
8.1. Asia-Pacific Non-Insulin Therapies For Diabetes Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Non-Insulin Therapies For Diabetes Market
9.1. China Non-Insulin Therapies For Diabetes Market Overview
9.2. China Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Non-Insulin Therapies For Diabetes Market
10.1. India Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Non-Insulin Therapies For Diabetes Market
11.1. Japan Non-Insulin Therapies For Diabetes Market Overview
11.2. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Non-Insulin Therapies For Diabetes Market
12.1. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Non-Insulin Therapies For Diabetes Market
13.1. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Non-Insulin Therapies For Diabetes Market
14.1. South Korea Non-Insulin Therapies For Diabetes Market Overview
14.2. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Non-Insulin Therapies For Diabetes Market
15.1. Western Europe Non-Insulin Therapies For Diabetes Market Overview
15.2. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Non-Insulin Therapies For Diabetes Market
16.1. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Non-Insulin Therapies For Diabetes Market
17.1. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Non-Insulin Therapies For Diabetes Market
18.1. France Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Non-Insulin Therapies For Diabetes Market
19.1. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Non-Insulin Therapies For Diabetes Market
20.1. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Non-Insulin Therapies For Diabetes Market
21.1. Eastern Europe Non-Insulin Therapies For Diabetes Market Overview
21.2. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Non-Insulin Therapies For Diabetes Market
22.1. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Non-Insulin Therapies For Diabetes Market
23.1. North America Non-Insulin Therapies For Diabetes Market Overview
23.2. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Non-Insulin Therapies For Diabetes Market
24.1. USA Non-Insulin Therapies For Diabetes Market Overview
24.2. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Non-Insulin Therapies For Diabetes Market
25.1. Canada Non-Insulin Therapies For Diabetes Market Overview
25.2. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Non-Insulin Therapies For Diabetes Market
26.1. South America Non-Insulin Therapies For Diabetes Market Overview
26.2. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Non-Insulin Therapies For Diabetes Market
27.1. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Non-Insulin Therapies For Diabetes Market
28.1. Middle East Non-Insulin Therapies For Diabetes Market Overview
28.2. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Non-Insulin Therapies For Diabetes Market
29.1. Africa Non-Insulin Therapies For Diabetes Market Overview
29.2. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Non-Insulin Therapies For Diabetes Market Competitive Landscape And Company Profiles
30.1. Non-Insulin Therapies For Diabetes Market Competitive Landscape
30.2. Non-Insulin Therapies For Diabetes Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis
30.2.5. The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
31. Non-Insulin Therapies For Diabetes Market Other Major And Innovative Companies
31.1. AstraZeneca plc
31.2. Novartis AG
31.3. GSK plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Eli Lilly and Company
31.6. Novo Nordisk A/S
31.7. Boehringer Ingelheim International GmbH
31.8. Les Servier Laboratories
31.9. Sumitomo Dainippon Pharma Co. Ltd.
31.10. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
31.11. Uni-Bio Science Group Ltd.
31.12. Intarcia Therapeutics
31.13. Janssen Pharmaceuticals
31.14. Boan Biotech
31.15. SatRx LLC
32. Global Non-Insulin Therapies For Diabetes Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Non-Insulin Therapies For Diabetes Market
34. Recent Developments In The Non-Insulin Therapies For Diabetes Market
35. Non-Insulin Therapies For Diabetes Market High Potential Countries, Segments and Strategies
35.1 Non-Insulin Therapies For Diabetes Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Insulin Therapies For Diabetes Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Insulin Therapies For Diabetes Market In 2029 - Growth Strategies
